2 Beaten-Down Stocks to Avoid
Over the past year, Editas Medicine (NASDAQ: EDIT) and Sarepta Therapeutics (NASDAQ: SRPT), two biotech companies, have encountered severe headwinds that aren't at all related to broader market volatility. Both drugmakers have seen their shares plummet over the trailing-12-month period. However, while investors are supposed to buy low, even at current levels, Editas Medicine and Sarepta aren't attractive stocks to buy.
Let's consider why investors should stay a safe distance away from these two biotech companies.
Image source: Getty Images.
Source Fool.com
Sarepta Therapeutics Stock
€15.64
-0.260%
The community is currently still undecided about Sarepta Therapeutics with 2 Buy predictions and 0 Sell predictions.
With a target price of 135 € there is potential for a 763.17% increase which would mean more than doubling the current price of 15.64 € for Sarepta Therapeutics.
